earnings
Pharmaron Forecasts Double-Digit Revenue Growth for Interim 2026 Results
Pharmaron forecast double-digit revenue growth for its interim 2026 results.
Markets open original ↗
Importance is a model-assigned 1–5 on published stories, not a market forecast.
Impact on a scheduled row is a company-prominence tier (High/Medium from graph centrality and size; Low only on curated minor events), not a magnitude forecast.
An earnings date marked confirmed is company-confirmed by Yahoo Finance; estimated is not yet announced. Unmarked rows carry no recorded provenance.
Economic releases are macro and carry no industry, so they stay in every view. A release with no value has not printed yet and says so rather than showing a zero.
Upcoming events across the tracked universe; past events are archived, with outcomes added where available — curated and cited, never fabricated. A past row without one reads “outcome pending”.
A lock-up or index change row adds one line of arithmetic — shares becoming sellable, or shares index funds must buy, as a share of float — read off the prospectus or the index methodology, with both numbers cited in the row. It states the mechanics, not a price move. A lock-up date derived as IPO + 180 days stays estimated until the company states it.
Mon · 12 Oct · today
Tue · 13 Oct
Mon · 13 Jul
earnings
Pharmaron forecast double-digit revenue growth for its interim 2026 results.
Markets open original ↗
partnership
Kawasaki Heavy Industries won an order from Daito for a 260-ton electric tugboat system.
Markets open original ↗
funding
Iberdrola's Neoenergia unit will invest EUR 2.4 billion in Brazil's northeast power grid.
Markets open original ↗
earnings
TCL Zhonghuan projects a first-half net loss of RMB 3.0 to 3.3 billion.
Markets open original ↗
earnings
Globalstar reported a significant Q1 2026 EPS miss with revenue disclosures omitted.
Markets open original ↗